<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998176</url>
  </required_header>
  <id_info>
    <org_study_id>471-19-FB</org_study_id>
    <nct_id>NCT03998176</nct_id>
  </id_info>
  <brief_title>Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE</brief_title>
  <acronym>BASE</acronym>
  <official_title>A Phase 4, Single-Arm Study of the Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Patients With Active Illicit Substance Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of bictegravir/emtricitabine/tenofovir
      alafenamide (B/F/TAF) in HIV-1 infected patients who actively use illicit substances. The
      study will also evaluate retention in care and adherence to B/F/TAF by self-report and
      pharmacokinetic analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, single-arm, prospective, pilot study to evaluate the effectiveness
      and safety of B/F/TAF in viremic HIV-1 infected treatment naive or experienced patients with
      active illicit substance use outside of nicotine, alcohol, and marijuana use.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with HIV-1 RNA &lt; 50 copies/mL as Determined by the FDA-defined Snapshot Algorithm</measure>
    <time_frame>Week 24</time_frame>
    <description>The percentage of participants achieving HIV-1 RNA &lt; 50 copies/mL at Week 24 analyzed by the snapshot algorithm, which defines a participants virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Grade 3 or Greater Adverse Events</measure>
    <time_frame>Week 24</time_frame>
    <description>The percentage of participants experiencing grade 3 or greater adverse events at Week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Grade 3 or Greater Adverse Events</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants experiencing grade 3 or greater adverse events at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HIV-1 RNA &lt; 50 copies/mL as Determined by the FDA-defined Snapshot Algorithm</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants achieving HIV-1 RNA &lt; 50 copies/mL at Week 48 analyzed by the snapshot algorithm, which defines a participants virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>B/F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive B/F/TAF for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bictegravir/emtricitabine/tenofovir alafenamide</intervention_name>
    <description>B/F/TAF single tablet formulation</description>
    <arm_group_label>B/F/TAF</arm_group_label>
    <other_name>Biktarvy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection

          -  Treatment naive or experienced

          -  Self-reported illicit substance use or confirmed urine drug screen within past 6
             months of any of the following: cocaine, heroin, methamphetamine, MDMA, phencyclidine,
             ketamine, gamma hydroxybutyrate, cathiniones, or inappropriate prescription opiate,
             benzodiazepine or stimulant use (excluding nicotine, alcohol, marijuana for criteria)

          -  HIV RNA &gt;1000 copies/mL

          -  Creatinine clearance &gt; 30 mL/min (Cockroft-Gault)

          -  ALT and AST &lt; 5 times the upper limit of normal

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  History of integrase or tenofovir related HIV resistance mutations

          -  Pregnancy

          -  Serious illness requiring systemic treatment and/or hospitalization within 30 days
             prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Havens, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska Medical Center, HIV Program</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jen O'Neill, RN</last_name>
    <phone>402-559-4312</phone>
    <email>jloneill@unmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mo Kubat, RN</last_name>
    <phone>402559-4408</phone>
    <email>mo.kubat@unmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Specialty Care Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-8106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Havens, PharmD</last_name>
      <phone>402-559-2674</phone>
      <email>jhavens@unmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Josh Havens</investigator_full_name>
    <investigator_title>Clinical Pharmacist, HIV Program</investigator_title>
  </responsible_party>
  <keyword>Substance use</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

